Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC

Peter Emtage
Published: Saturday, Sep 27, 2014

Peter Emtage, vice president, immune mediated therapies, MedImmune, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

These two molecules have different impacts on immune response, Emtage says. Preclinical studies have shown that synergies exist between the two molecules. This combination is being looked at in several indications to determine where these synergies exist.

Researchers saw some exciting and promising activity in this small study, Emtage says. The combination demonstrated an adequate level of tolerability to be studied further.

<<< View more from the 2014 ESMO Congress

Peter Emtage, vice president, immune mediated therapies, MedImmune, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

These two molecules have different impacts on immune response, Emtage says. Preclinical studies have shown that synergies exist between the two molecules. This combination is being looked at in several indications to determine where these synergies exist.

Researchers saw some exciting and promising activity in this small study, Emtage says. The combination demonstrated an adequate level of tolerability to be studied further.

<<< View more from the 2014 ESMO Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x